A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
October 24th, 2015
The metastatic spread of cancer is the major cause of cancer-related deaths. We provide an in-depth description of our survival surgery methodology for establishing a “patient-like” orthotopic syngeneic mouse model system for studying the mechanisms of metastasis in solid organ tumors.
The overall goal of this procedure is to establish a patient like Orthotopic Syngeneic mouse model system for studying the mechanisms of metastasis in hepatocellular carcinoma. This is accomplished by first preparing mouse hepatocellular carcinoma cells for implantation. In the second step, the abdomen of a recipient syngeneic animal is opened and the cells are carefully injected into the right lobe of the liver.
Ultimately, the success and reproducibility of this methodology recommends it for widespread use in elucidating the biological mechanisms of hepatocellular carcinoma metastasis. The main advantage of this technique over existing techniques like mouse xenograft tumor models, is that our syn genetic tumor model system allows the investigation of the role of the immune response in tumor metastasis. Demonstrating this procedure with me will be Michelle Nadu, an undergraduate student from our lab To prepare the cells for implantation begin by washing a 60 to 70%confluent culture of hepatocellular carcinoma cells two times with five milliliters of PBS.
Incubate the cell culture with two milliliters of trypsin at 37 degrees Celsius. After five minutes, count the cells and dilute them at five times 10 to the fifth cells per milliliter of PBS. Next, transfer 100 microliter aliquots of the cells into one sterile 1.5 milliliter micro centrifuge tube per mouse, and place the cells on ice.
Before beginning the surgical procedure, confirm the proper level of anesthesia by toe. Pinch, apply ointment to the eyes of a 16 to 20 gram healthy adult bsy mouse and shave in approximately one inch area around the midline of the animal's abdomen. Then dawn a pair of latex gloves and wash the exposed skin several times with a soapy disinfectant scrub, followed by a sterile PBS rinse for approximately five minutes.
When the skin has been prepared, discard the gloves and put on the appropriate personal protective equipment. Provide an external heat source to prevent anesthetic hypothermia during the procedure, and then place surgical tape on the animal's, limbs and tail to fix the mouse in a supine position. Next, make a straight incision immediately inferior to the xiphos sternum, and use a sterile self retaining surgical retractor to open the abdomen.
When the liver is visible, aspirate one aliquot of cells into a one milliliter syringe equipped with a 20 gauge needle, and slowly and carefully inject all 100 microliters of the hepatocellular carcinoma cells into the right lobe of the liver. After removing the needle, apply a sterile cotton swab for at least one minute to stop any bleeding. Then use an absorbable suture to close the subcutaneous tissue, followed by closure of the skin.
With surgical clips, clean the wound with another disinfectant scrub and subcutaneously, administer 100 microliters of normal saline. Then immediately after the surgery, transfer the mouse to a clean cage without companions and with paper bedding for at least 24 hours. These BSY mouse livers were implanted with five times 10 to the six one ME.A mouse hepatocellular carcinoma cells as just demonstrated.
Clinic clinical evidence of hepatocellular carcinoma development was observable 63 days later as indicated by the arrow in one mouse. A superficial tumor was observed on the surface of the liver with some attachment to the abdominal wall. The lungs from this mouse exhibited an abnormal morphology as well displaying areas of visible hemorrhaging necrosis.
In a second mouse, the liver appeared grossly abnormal with the abnormality very strongly resembling a superficial tumor as expected control. Mice that were not implanted did not develop tumors in either the liver or the lungs. Once mastered, this orthotopic syn genetic mouse model can provide a good platform for elucidating the biological mechanisms of metastasis and hepatocellular carcinoma.
View the full transcript and gain access to thousands of scientific videos
Overview
This article describes a methodology for establishing a patient-like orthotopic syngeneic mouse model to study metastasis in hepatocellular carcinoma. The approach allows for the investigation of immune response roles in tumor metastasis, providing a significant advantage over traditional xenograft models.
Key Study Components
Area of Science
- Oncology
- Mouse Models
- Metastasis Research
Background
- Metastatic spread is a leading cause of cancer-related deaths.
- Understanding the mechanisms of metastasis is crucial for developing effective therapies.
- Current models have limitations in studying immune interactions.
- This study presents a novel syngeneic model for better insights.
Purpose of Study
- To establish a reliable model for studying hepatocellular carcinoma metastasis.
- To explore the immune response's role in tumor progression.
- To enhance reproducibility in experimental cancer research.
Methods Used
- Preparation of hepatocellular carcinoma cells for implantation.
- Surgical implantation of cells into the liver of a syngeneic mouse.
- Monitoring of tumor development and metastasis.
- Evaluation of immune response interactions with tumor growth.
Main Results
- The methodology successfully established a patient-like model.
- Demonstrated reproducibility in tumor growth and metastasis studies.
- Highlighted the immune system's involvement in tumor behavior.
- Recommended for broader application in cancer research.
Conclusions
- This model provides a valuable tool for studying cancer metastasis.
- It offers insights into the immune response's role in tumor dynamics.
- Encourages further research into therapeutic strategies targeting metastasis.
Frequently Asked Questions
Executive Industry Relevance
Metastasis remains the principal driver of cancer mortality, yet mechanistic understanding and translational modeling are limited by inadequate preclinical systems. This orthotopic syngeneic mouse model of hepatocellular carcinoma metastasis enables biologically relevant interrogation of metastatic processes within an immune-competent, organ-specific context. Its reproducibility and immune system fidelity position it as a critical asset for early discovery and mechanistic de-risking in oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic dissection of metastatic progression in a disease-relevant system.
- Supports functional validation of metastasis-related targets in an immune-competent host.
- Facilitates biological de-risking by modeling tumor-host and immune interactions.
- Improves predictive confidence for target selection and triage in oncology portfolios.
Screening & Assay Development
- Provides a validated in vivo platform for evaluating anti-metastatic agents in a reproducible setting.
- Supports quantitative assessment of metastatic burden and tumor growth in primary and secondary sites.
- Enables standardization of preclinical efficacy endpoints for compound screening.
- Allows for the development of immune-modulatory assay readouts relevant to human disease.
Translational & Preclinical Research
- Aligns preclinical modeling with patient-like metastatic disease for translational continuity.
- Permits evaluation of immune-targeted therapies in a syngeneic, organ-specific context.
- Supports risk-adjusted advancement of candidates with demonstrated anti-metastatic activity.
- Facilitates biomarker discovery linked to metastatic progression and immune response.
Pipeline & Workflow Integration
This model integrates at the interface of early discovery and preclinical validation, bridging mechanistic studies and translational research in metastatic oncology.
- Discovery Biology: Enables hypothesis-driven testing of metastatic mechanisms and immune interactions.
- Screening: Provides a reproducible, quantitative in vivo system for compound efficacy evaluation.
- Analytics: Supports measurement of tumor burden, metastatic spread, and immune response metrics.
- Translational Research: Offers continuity from mechanistic discovery to preclinical candidate validation in a patient-like setting.
- Enterprise Reuse: Establishes a standardized, scalable platform for ongoing oncology R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in metastasis research.
- Operational Value: Delivers reproducibility, standardization, and scalability for preclinical studies.
- Strategic Value: Improves go/no-go decision quality and capital allocation in oncology pipelines.
- Portfolio Impact: Enables risk-adjusted prioritization of anti-metastatic and immune-modulatory candidates.
Implementation Considerations
- Requires expertise in surgical implantation and animal model management.
- Demands access to immune-competent mouse strains and validated cell lines.
- Necessitates cross-team standardization of surgical, monitoring, and analytical protocols.
- Adaptation to other solid tumor types may require additional validation.
- Practical limitations include surgical skill requirements and animal welfare considerations.
